BioCryst Pharmaceuticals, Inc. Forecast, price target & analysts
BioCryst Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
BioCryst Pharmaceuticals, Inc. Classifications & Recommendation:
BioCryst Pharmaceuticals, Inc. Price Target
| Target Price | $15.20 |
| Price | $7.33 |
| Potential |
107.37%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target BioCryst Pharmaceuticals, Inc. 2026 .
The average BioCryst Pharmaceuticals, Inc. target price is $15.20.
This is
107.37%
register free of charge
$30.00
309.28%
register free of charge
$8.00
9.14%
register free of charge
|
|
| A rating was issued by 10 analysts: 9 Analysts recommend BioCryst Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BioCryst Pharmaceuticals, Inc. stock has an average upside potential 2026 of
107.37%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 450.71 | 563.66 |
| 36.00% | 25.06% | |
| EBITDA Margin | -0.29% | 10.73% |
| 99.06% | 3,820.09% | |
| Net Margin | -19.90% | -2.70% |
| 73.20% | 86.43% |
8 Analysts have issued a sales forecast BioCryst Pharmaceuticals, Inc. 2025 . The average BioCryst Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast BioCryst Pharmaceuticals, Inc. 2025 . The average BioCryst Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 BioCryst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average BioCryst Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.43 | -0.07 |
| 63.56% | 83.72% | |
| P/E | negative | |
| EV/Sales | 3.64 |
10 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast for earnings per share. The average BioCryst Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
BioCryst Pharmaceuticals, Inc....
Current BioCryst Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Feb 25 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Jan 31 2025 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Feb 25 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 25 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Feb 25 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Jan 31 2025 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Jan 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
